Sophia GeneticsFRA:90B +4.18%74 PS Ratio is 4.90 as of Jul. 11, 2026, which is 12% above its 10-year median of 4.36. GuruFocus rates FRA:90B with a GF Score™ of 74/100 and a GF Value™ of €4.15 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 659 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 80.58% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sophia Genetics's share price is €4.98.
Sophia Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.02. Hence, Sophia Genetics's PS Ratio for today is 4.90.
Warning Sign:
Sophia Genetics SA stock PS Ratio (=4.92) is close to 3-year high of 5.46.
The historical rank and industry rank for Sophia Genetics's PS Ratio or its related term are showing as below:
FRA:90B'
s PS Ratio Range Over the Past 10 Years
Min: 2.67 Med: 4.36 Max: 29.48
Current: 5.13
During the past 8 years, Sophia Genetics's highest PS Ratio was 29.48. The lowest was 2.67. And the median was 4.36.
FRA:90B's PS Ratio is ranked worse than 80.58% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.48
vs FRA:90B: 5.13
During the past 12 months, the average Revenue per Share Growth Rate of Sophia Genetics was 16.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.60% per year.
During the past 8 years, Sophia Genetics's highest 3-Year average Revenue per Share Growth Rate was 17.70% per year. The lowest was 10.50% per year. And the median was 13.75% per year.
Back to Basics: PS Ratio
Sophia Genetics (FRA:90B) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sophia Genetics PS Ratio Related Terms
Sophia Genetics PS Ratio Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sophia Genetics's Share Price of today is €4.98. Sophia Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sophia Genetics (FRA:90B) has a PS Ratio of 4.90 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sophia Genetics and its competitors. This is 12% above median its historical median of 4.36. Over the past decade, Sophia Genetics' PS Ratio has ranged from 2.67 to 29.48. According to the industry distribution chart, Sophia Genetics ranks #531 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 80.6%.
Is Sophia Genetics' PS Ratio too high?
Sophia Genetics' current PS Ratio of 4.90 is 12% above median its 10-year median of 4.36. Over the past 10 years, this metric has ranged from a low of 2.67 to a high of 29.48. The Healthcare Providers & Services industry median PS Ratio is 1.48. Sophia Genetics' value of 4.90 is 231.1% above this industry median. Based on the distribution chart, Sophia Genetics ranks #531 out of 659 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' PS Ratio compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #531 out of 659 companies for PS Ratio. This places Sophia Genetics in the lower half of its industry. The industry median PS Ratio is 1.48. Sophia Genetics' value of 4.90 is 231.1% above this benchmark. Historically, Sophia Genetics' own PS Ratio has ranged from 2.67 to 29.48 over the past decade. While the company's 10-year median is 4.36 vs. the industry median of 1.48, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current PS Ratio of 4.90 is 231.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current PS Ratio is 4.90, which is 12% above median its own 10-year median of 4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €4.98 — trading 20% above its estimated fair value. The current PS Ratio is 4.90, which is 12% above median its 10-year median of 4.36 and 231.1% above the Healthcare Providers & Services industry median of 1.48. Sophia Genetics' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current PS Ratio is 4.90 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (FRA:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €4.98 is trading 20% above its estimated GF Value™ of €4.15.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for FRA:90B:
PS Ratio: 4.90 (12% above median its 10-year median of 4.36)
GF Value™: €4.15 vs. price of €4.98 (20% above fair value)
Industry Position: 231.1% above the Healthcare Providers & Services median (#531 of 659)
No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
74GF Score
Get the complete analysis for FRA:90B
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:90B has been successfully added to your 
